← All trials
NCT06069570
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 7, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Jan 31, 2027
- First posted
- Oct 6, 2023
- Last posted
- Dec 15, 2023
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kiromic BioPharma Inc.Lead sponsor
- Statistics & Data CorporationCollaborator
- University of PittsburghOverall official - principal investigator
- University of PittsburghOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.